AUTHOR CONTRIBUTIONS
K Giuliano – concept/design, data analysis/interpretation, drafting article, critical revision of article, approval of article
J Canner – statistics, data analysis/interpretation, approval of article
E Etchill – concept/design, data analysis/interpretation, critical revision of article, approval of article
A Suarez-Pierre – concept/design, critical revision of article, approval of article
CW Choi – data analysis/interpretation, critical revision of article, approval of article
RSD Higgins – data analysis/interpretation, critical revision of article, approval of article
S Hsu – data analysis/interpretation, critical revision of article, approval of article
K Sharma – data analysis/interpretation, critical revision of article, approval of article
A Kilic – concept/design, data analysis/interpretation, critical revision of article, approval of article
REFERENCES:
1. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc . 1969;1(1):106-112.
2. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation.Transplantation . 2005;80(2 Suppl):S254-264.
3. Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA . 2011;306(17):1891-1901
4. Penn I. The price of immunotherapy. Curr Probl Surg . 1981;18(11):681-751.
5. Penn I. Incidence and treatment of neoplasia after transplantation.J Heart Lung Transplant Off Publ Int Soc Heart Transplant . 1993;12(6 Pt 2):S328-336.
6. Penn I. Post-transplant malignancy: the role of immunosuppression.Drug Saf . 2000;23(2):101-113.
7. Crespo-Leiro MG, Alonso-Pulpón L, Vázquez de Prada JA, et al. Malignancy after heart transplantation: incidence, prognosis and risk factors. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg . 2008;8(5):1031-1039.
8. Asleh R, Clavell AL, Pereira NL, et al. Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation. J Am Coll Cardiol . 2019;73(21):2676-2688.
9. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match. J Heart Lung Transplant Off Publ Int Soc Heart Transplant . 2019;38(10):1056-1066.
10. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature . 1999;397(6719):530-534.
11. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation . 2003;76(3):597-602.
12. Engl T, Makarević J, Relja B, et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer . 2005;5:4.
13. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med . 2009;150(9):604-612.
14. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med . 2012;367(1):20-29.
15. Youn J-C, Stehlik J, Wilk AR, et al. Temporal Trends of De Novo Malignancy Development After Heart Transplantation. J Am Coll Cardiol . 2018;71(1):40-49.
16. Higgins RS, Brown RN, Chang PP, et al. A multi-institutional study of malignancies after heart transplantation and a comparison with the general United States population. J Heart Lung Transplant Off Publ Int Soc Heart Transplant . 2014;33(5):478-485.
17. Rivinius R, Helmschrott M, Ruhparwar A, et al. Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy. Drug Des Devel Ther . 2015;9:93-102.
18. Kellerman L, Neugut A, Burke B, Mancini D. Comparison of the incidence of de novo solid malignancies after heart transplantation to that in the general population. Am J Cardiol . 2009;103(4):562-566.
19. Lateef N, Abdul Basit K, Abbasi N, Kazmi SMH, Ansari AB, Shah M. Malignancies After Heart Transplant. Exp Clin Transplant Off J Middle East Soc Organ Transplant . 2016;14(1):12-16.
20. Mancini D, Rakita V. Malignancy Post Heart Transplantation. J Am Coll Cardiol . 2018;71(1):50.
21. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet Lond Engl . 1999;354(9173):93-99.
22. Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol . 2010;23(3):253-262.
23. Mandayam S, Shahinian VB. Are chronic dialysis patients at increased risk for cancer? J Nephrol . 2008;21(2):166-174.
24. Fried LF, Katz R, Sarnak MJ, et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol JASN . 2005;16(12):3728-3735.
25. Wong G, Hayen A, Chapman JR, et al. Association of CKD and cancer risk in older people. J Am Soc Nephrol JASN . 2009;20(6):1341-1350.
26. Vajdic CM, McDonald SP, McCredie MRE, et al. Cancer incidence before and after kidney transplantation. JAMA . 2006;296(23):2823-2831.